Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, Moderna announced that promising clinical, safety, and translational data from its Phase 1/2 study evaluating the investigational immune-evasion targeted cancer antigen therapy/CAT mRNA-4359 would be presented at the 2025 European Society for Medical Oncology/ESMO Congress.
mRNA-4359 is an immune-evasion targeted CAT that encodes epitopes of two common immune escape pathways: PD-L1 and IDO1. Its dual mechanism of action is designed to elicit antigen-specific T-cell responses to both directly kill tumor cells expressing PD-L1 and IDO1, and deplete immunosuppressive cells in the tumor microenvironment, aiming to establish an immune-permissive state for sustained anti-tumor activity.
Across all evaluable patients, the therapy demonstrated an objective response rate of 24% and a disease control rate of 60%. It continues to be evaluated as a monotherapy and in combination with pembrolizumab in patients with advanced melanoma and non-small cell lung cancer/NSCLC.
Moderna Inc. is a biotechnology company that provides messenger RNA medicines in the United States, Europe, and internationally.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
